What is Bevespi Aerosphere?
Bevespi Aerosphere is a combined preventative inhaler for COPD. It contains a long-acting muscarinic agonist (LAMA) and a long-acting beta-2 agonist (LABA) that work together to open your airways, so you can breathe easier.
What is Bevespi Aerosphereโs active ingredient?
Bevespi Aerosphere has two active ingredients: glycopyrrolate, a LAMA, and formoterol fumarate, a LABA. Evidence suggests that combined therapy with a LAMA and a LABA is more effective than just using one or the other, based on the risk of COPD symptoms and hospitalisations.[1]
How does Bevespi Aerosphere work?
Because Bevespi Aerosphere contains two active ingredients, it works in two complementary ways to help prevent COPD symptoms.
The first ingredient, glycopyrrolate, is a LAMA, which means it blocks a neurotransmitter called acetylcholine, which causes muscles around your airways to narrow. This relaxes these muscles, opening up your airways to allow more air to pass through.[2]
The second, formoterol fumarate, is a LABA, which binds to beta-2-adrenergic-receptors on the smooth muscle in your airways, opening them them up to improve airflow in and out of your lungs.[3]
How do Bevespi Aerosphere doses work?
In the US, Bevespi Aerosphere comes in one dose: 9 mcg/4.8 mcg. Youโll usually take two inhalations at a time, for a combined dose of 18 mg glycopyrrolate, and 9.6 mcg formoterol fumarate.
How we source info.
When we present you with stats, data, opinion or a consensus, weโll tell you where this came from. And weโll only present data as clinically reliable if itโs come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.